scholarly journals Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil

2019 ◽  
Author(s):  
Luisa Von Zuben Vecoso ◽  
Tais Freire Galvao ◽  
Marcus Silva ◽  
Everton Silva ◽  
Mariangela Resende
Keyword(s):  
Cost Effectiveness ◽  
Health System ◽  
Influenza A ◽  
Cost Effective ◽  
Cost Effectiveness Ratio ◽  
Tree Model ◽  
Unified Health System ◽  
Effectiveness Analysis ◽  
Influenza A H1n1 ◽  
Effectiveness Data

BACKGROUND: Oseltamivir and zanamivir have indication for treating symptomatic flu and in prophylaxis in epidemics for groups with high risk of complications. METHODS: Effectiveness data was identified in literature review, and costs were obtained from official systems and micro-costing. RESULTS: We adopted a decision-tree model to assess the effectiveness of chemoprophylaxis in Brazilian Unified Health System (SUS) perspective with willingness to pay BRL 30,000.00/QALY. The incremental cost-effectiveness ratio for chemoprophylaxis compared to no prophylaxis was - 2,921.14/QALY. CONCLUSION: Chemoprophylaxis is cost-effective in Brazilian scenario.

scholarly journals Cost-Effectiveness Analysis Kloramfenikol Dan Seftriakson Untuk Pengobatan Demam Tifoid Pada Pasien Dewasa Di Rumah Sakit Sanglah Denpasar

2019 ◽  
Vol 2 (2) ◽  
pp. 105-112
Author(s):  
Amelia Lorensia ◽  
Doddy De Queljoe ◽  
Made Dwike Swari Santi
Keyword(s):  
Cost Effectiveness ◽  
Length Of Stay ◽  
Typhoid Fever ◽  
Medical Records ◽  
Cost Effective ◽  
Cost Effectiveness Ratio ◽  
Hospital Perspective ◽  
Effectiveness Analysis ◽  
The Cost ◽  
Two Alternatives

The number of typhoid fever patient in Indonesia is still high. Typhoid fever can be treated by antibiotic therapy such as chloramphenicol and ceftriaxone. The purpose of this study was to compare the cost-effectiveness of chloramphenicol and ceftriaxone which was given to adult patients who were diagnosed with typhoid fever in Sanglah Denpasar Hospital. A comparative study between two alternatives was conducted using the hospital perspective. Retrospective method was used to collect data from patient medical records, who was diagnosed and hospitalized in Sanglah Denpasar Hospital during January 2017 until July 2018. The cost analysis was perform using cost-effectiveness grid and cost-effectiveness ratio (ACER) methods. Cost-effectiveness grid showed that dominant of ceftriaxone for patient with typhoid fever. ACER analysis for ceftriaxone was IDR 2,097,170.88 with effectivenes (length of stay) 4.27 days, and was IDR 2,097,170.88 with effectiveness (the time of reaching normal temperature) 2.42 days. ACER analysis for chloramphenicol was IDR 2,555,464.22        with effectivenes (length of stay) 10.22 days, and was IDR 2,555,464.22 with effectiveness (the time of reaching normal temperature) 3.44 days. ACER analysis showed lower degree of ceftriaxone and higher effectiveness based on length of stay and the time of reaching normal temperature. The conclusion of this study is that ceftriaxone is more cost-effective than chloramphenicol.

scholarly journals Cost-effectiveness analysis and budgetary impact of antipsychotics available in the Brazilian Unified Health System

2020 ◽  
Vol 12 (3) ◽  
pp. 195-205
Author(s):  
Cid Manso de Mello Vianna ◽  
◽  
Ricardo Ribeiro Alves Fernandes ◽  
Gabriela Bittencourt Gonzalez Mosegui ◽  
Valéria Queiroz Pagnin ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Health System ◽  
Impact Analysis ◽  
Cost Effective ◽  
Lifetime Horizon ◽  
Budgetary Impact ◽  
Unified Health System ◽  
Cost Strategy ◽  
Schizophrenic Patients ◽  
Effective Choice

Objective: To carry out a cost-effectiveness and budget impact analysis of antipsychotic use in adults to treat schizophrenia from the perspective of the Unified Health System (SUS). Methods: A Markov model simulated the treatment of schizophrenic patients with an initial average age of 25 years and a lifetime horizon. The possibility of combining drugs resulted in 20 pharmacotherapeutic strategies. Results: The lowest-cost strategy, risperidone/olanzapine, obtained values of $45,092.77 with effectiveness of 15.97 QALY. The incremental cost-effectiveness ratio in dollars/QALY of olanzapine/risperidone was 2,470.24, and risperidone/ziprasidone was 352,671.90, compared to the first option. All other therapeutic combinations were dominated. The budgetary impact assessment indicated that the most cost-effective choice could generate savings of US$ 1,555.00 on average, per patient, over five years. Conclusion: The therapeutic proposal with the lowest cost per patient was risperidone combined with olanzapine, revealing these two drugs as a strategy with lower budgetary impact and better cost-effectiveness.

scholarly journals ANALISIS EFEKTIVITAS BIAYA PADA PASIEN ANAK DEMAM TIFOID DI RUMAH SAKIT BHAYANGKARA MANADO

PHARMACON ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 335
Author(s):  
Agatha Agnes ◽  
Gayatri Citraningtyas ◽  
Sri Sudewi
Keyword(s):  
Cost Effectiveness ◽  
Typhoid Fever ◽  
Incremental Cost ◽  
Pediatric Patients ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Incremental Cost Effectiveness Ratio ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis ◽  
Record Data

ABSTRACT Typhoid fever is an endemic disease which it incidence rate is still high in Indonesian. Administering antibiotic therapy can do treatment of typhoid fever. This study was conducted since there are several pediatric patients diagnosed with typhoid fever but have different antibiotic therapies, namely cefotaxime and ceftriaxone therapy, so it is necessary to do calculations to determine the comparison and determine which treatment is more efficient in cost and effectiveness. The method used in this study is CEA (Cost-Effectiveness Analysis) with the design of retrieving medical record data of children with typhoid fever in Bhayangkara Manado Hospital retrospectively from January to December 2018. The samples  obtained were 28 pediatric patients, cinsisting of 12 patients using cefotaxime therapy and 16 patients using ceftriaxone therapy. The result of ACER (An Avarage Cost Effective Ratio) obtained by ceftriaxone were Rp. 526.609,-/day and cefotaxime Rp. 484.789,-/day. In this study, if patients under cefotaxime therapy want to swich treatment to ceftriaxone therapy, ICER calculation (Incremental Cost-Effectiveness Ratio) is carried out the result are Rp.340.528,-. Keyword: Typhoid fever, Antibiotics, CEA (Cost-Effectiveness Analysis) ABSTRAK Demam tifoid merupakan penyakit endemik yang angka kejadiannya masih tinggi di Indonesia. Pengobatan demam tifoid dapat diobati dengan cara pemberian terapi antibiotik. Penelitian ini dilakukan karena ada beberapa pasien anak yang di diagnosa demam tifoid tetapi memiliki terapi antibiotik yang berbeda, yaitu terapi sefotaksim dan seftriakson  sehingga perlu dilakukan perhitungan untuk mengetahui perbandingan dan menentukan pemilihan pengobatan mana yang lebih efisien dalam biaya maupun efektivitas. Metode yang digunakan dalam penelitian ini adalah CEA (Cost-Effectiveness Analysis) dengan rancangan pengambilan data rekam medik pasien anak demam tifoid di RS. Bhayangkara Manado secara retrospektif pada periode Januari – Desember 2018. Sampel yang didapat sebanyak 28 pasien anak, yang terdiri dari 12 pasien pengguna terapi sefotaksim dan 16 pasien pengguna terapi seftriakson. Hasil ACER (An Avarage Cost Effective Ratio) yang diperoleh sefotaksim Rp.526.609,-/hari dan seftriakson Rp.484.789,-/hari. Pada penelitian ini jika pasien terapi sefotaksim ingin berpindah pengobatan ke terapi seftriakson maka dilakukan perhitungan ICER (Incremental Cost-Effectiveness Ratio) dan didapat hasil Rp.340.582,-, sehingga jika ingin berpindah pengobatan maka perlu penambahan biaya sesuai nilaI ICER.Kata Kunci : Demam Tifoid, Antibiotik, CEA (Cost-Effectiveness Analysis).

scholarly journals Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 53-63 ◽  
Author(s):  
Yu Chen ◽  
Peng Ye ◽  
Chongwu Ren ◽  
Pengfei Ren ◽  
Zheng Ma ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Liver Injury ◽  
Controlled Trial ◽  
Cost Effective ◽  
Unit Price ◽  
Sensitivity Analyses ◽  
Expert Advice ◽  
Cost Effectiveness Ratio ◽  
Tree Model ◽  
The Cost

AbstractTo evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury (anti-TB DILI).MethodsIn the construction of a decision tree model, the efficacy and safety parameters came from the results of the randomized, controlled trial conducted here, the effect parameters were derived from expert advice, and the cost parameters, such as usage specification, number, and unit price, came from literature, expert advice, and so on.ResultsThe cost-effectiveness analysis (CEA) based on the effect degrees showed that bicyclol had the best effect (4.63562). The incremental cost-effectiveness ratio (ICER) (206.03270) of bicyclol was the lowest. The cost-effectiveness ratio of silibinin was the lowest (68.59987). The CEA based on the complete normalization rate showed that bicyclol had the highest complete normalization rate (83.562%), the lowest cost-effectiveness ratio (4.63627), and the smallest ICER (4.63504). Sensitivity analyses proved the robustness of the results.ConclusionsBicyclol is the most cost-effective therapy and the preferred choice for treating anti-TB DILI.

scholarly journals Model Comparisons of the Cost Effectiveness of Rubella Vaccination Method in Japanese Adults

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 233
Author(s):  
Tomoya Itatani ◽  
Ryo Horiike ◽  
Hisao Nakai ◽  
Kazuya Taira ◽  
Chika Honda ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Antibody Titer ◽  
Cost Effective ◽  
Tree Model ◽  
Pregnant Females ◽  
Congenital Rubella ◽  
Effectiveness Analysis ◽  
Japanese Adults ◽  
The Cost ◽  
Rubella Vaccination

The number of rubella cases has increased in Japan, especially among adults. Rubella infection in pregnant females can lead to congenital rubella syndrome (CRS). The Japanese government is promoting vaccination to prevent CRS. This study performs a cost-effectiveness analysis of the following four methods: (1) females who wished to become pregnant and partners, with an antibody-titer test; (2) females only, with an antibody-titer test; (3) females and males, without an antibody-titer test; (4) females only, without an antibody-titer test. A decision tree model with a hypothetical cohort of 500 males and 500 females was used for the analysis, and the parameters were obtained from previous studies. The number of avoidances of CRS was defined as the effect. Compared to the case where methods were not implemented, the number of CRS cases that can be prevented by implementing the methods was 0.0115589 by (1) and (3) and 0.0147891 by (2) and (4). The cost effectiveness of (1) to (4) was 287,413,677 JPY, 135,050,529 JPY, 388,524,974 JPY, and 197,744,219 JPY, respectively (1 JPY = 0.00963247 USD). Method (2) was the most cost-effective and did not change by sensitivity analysis. We conclude that the vaccination for females only with an antibody-titer test is recommended.

scholarly journals ANALISIS EFEKTIVITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN INFEKSI SALURAN KEMIH MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SEFOTAKSIM DI RS PARU ARIO WIRAWAN SALATIGA

2019 ◽  
Vol 1 (1) ◽  
pp. 20-26
Author(s):  
Kusumaning Wardhani ◽  
Ening Listyanti ◽  
Niken Dyahariesti ◽  
Richa Yuswantina
Keyword(s):  
Cost Effectiveness ◽  
Incremental Cost ◽  
Average Cost ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis

Infeksi Saluran Kemih (ISK) adalah keadaan dimana kuman bertumbuh dan berkembangbiak di dalam traktus urinarius dengan jumlah yang bermakna. ISK diobati dengan antibiotik yang menjadi salah satu kategori biaya yang signifikan dalam anggaran farmasi di rumah sakit. Antibiotik golongan Sefalosporin digunakan sebagai drug of choise dan dicari lebih cost-effective. Untuk menentukan terapi yang lebih cost-effective antara penggunaan Setriakson dan Sefotaksim pada pasien ISK di rawat inap di RS Paru Ario Wirawan Salatiga. Penelitian ini menggunakan metode penelitian deskriptif dengan pengambilan data secara retrospektif.Dianalisis dengan metode CEA dengan parameter Average Cost Effectiveness Ratio (ACER) dan Incremental Cost Effectiviness Ratio (ICER) dilihat dari outcome lama rawat inap. Sampel pada penelitian ini sebanyak 39 pasien diantaranya 22 pasien menggunakan Seftriakson dan 17 pasien menggunakan Sefotaksim. Hasil penelitian menunjukkan, nilai ACER kelas I Sefotaksim sebesar Rp. 454.353. Nilai ACER kelas II Sefotaksim sebesar Rp. 212.283 dan nilai ICER sebesar -Rp. 134.987/hari. Nilai ACER kelas III Seftriakson sebesar Rp. 268.366. Biaya antibiotik yang paling cost-effective pada kelas I adalah Sefotaksim, paling cost-effective pada kelas II adalah Sefotaksim, paling cost-effective pada kelas III adalah Seftriakson.

Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19398-e19398
Author(s):  
Wasamol Mahaparn ◽  
Chalermchai Lertanansit ◽  
Chanida Vinayanuwattikun ◽  
Suebpong Tanasanvimon
Keyword(s):  
Cost Effectiveness ◽  
Receptor Antagonist ◽  
Cost Effective ◽  
Drug Regimen ◽  
Cost Effectiveness Analysis ◽  
Nausea And Vomiting ◽  
High Dose ◽  
Tree Model ◽  
Effectiveness Analysis ◽  
Standard Strategy

e19398 Background: NK-1 receptor antagonist (NK1RA) is a standard anti-emetic agent in chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving high-dose (HD) cisplatin. However, in limited-resource settings, three-drug regimen including olanzapine, ondansetron and dexamethasone is affordable and effective in CINV prevention in these patients. Objectives: To evaluate cost effectiveness of additional NK1RA for CINV prevention in Thai patients receiving HD cisplatin in 3-cycle horizon, societal perspective. Methods: During January to December 2019, 20 patient receiving HD cisplatin were prospectively enrolled to receive standard three-drug regimen at King Chulalongkorn Memorial Hospital. Total medical resource utility, non-medical cost and clinical outcomes were actually collected and used for establishing decisional-tree model and cost-effectiveness analysis. Three arms decisional-tree model was constructed. First, standard strategy, a real-world practice in Thailand, patients received three-drug regimen in all cycles of chemotherapy. Second, NK1RA-rescue strategy, patients received three-drug regimen in the first cycle and additional NK1RA in subsequent cycles if the patients experienced CINV. Third, NK1RA upfront strategy, patients received four drug NK1RA-containing regimen in all cycles. Complete response (CR) rate was assumed to be 92.5% in NK1RA-containing regimen based on clinical trials. The study endpoint is to compare cost and QALYs in term of incremental cost-effectiveness ratio (ICER). Results: CR rates were 90% and 71% in first and second cycle in patients receiving standard regimen. The NK1RA upfront strategy produced greatest QALYs of 0.0351, followed by 0.0328 and 0.0292 in NK1RA-rescue strategy and standard strategy respectively. Mean total costs were 10420.46, 3332.19 and 2841.30 Thai baht (THB) respectively. The ICER of NK1RA-rescue strategy relative to standard strategy was 135,774 THB per QALY and the ICER of NK1RA upfront strategy relative to NK1RA-rescue strategy was 3,096,654 THB per QALY. Therefore, the ICER of NK1RA-rescue strategy but not NK1RA upfront strategy is considered to be cost effective at the willingness-to-pay level of 160,000 THB per QALY. Conclusions: Our findings suggested that the additional NK1RA as a rescue strategy is cost-effective in patients receiving HD cisplatin in Thai health care.

scholarly journals COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE GENERIC AND PATENT IN CHILDREN WITH TYPHOID

2018 ◽  
Vol 10 (1) ◽  
pp. 76
Author(s):  
Santi Purna Sari ◽  
Icut Diki Adestia Putri ◽  
Binar Nursanti
Keyword(s):  
Cost Effectiveness ◽  
Hospital Stay ◽  
Analytical Study ◽  
Length Of Hospital Stay ◽  
Cost Effective ◽  
Physician Service ◽  
Cost Effectiveness Ratio ◽  
Cross Sectional ◽  
Effectiveness Analysis ◽  
Laboratory Examinations

Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effectivetreatment.Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total samplingmethod. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectivenessof the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costsof drugs, laboratory examinations, medical device usage, physician service, and hospitalization.Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day.Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.

scholarly journals COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 399
Author(s):  
Arnold Hagens ◽  
Ahmet Çağkan İnkaya ◽  
Kasirga Yildirak ◽  
Mesut Sancar ◽  
Jurjen van der Schans ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Savings ◽  
Cost Effective ◽  
Incremental Cost Effectiveness Ratio ◽  
Vaccine Uptake ◽  
First Year ◽  
Cost Effectiveness Ratio ◽  
Scenario Analyses ◽  
Effectiveness Analysis ◽  
The Cost

As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people worldwide. Vaccination has started in most countries around the world. In this study, we estimated the cost-effectiveness of strategies for COVID-19 vaccination for Turkey compared to a baseline in the absence of vaccination and imposed measures by using an enhanced SIRD (Susceptible, Infectious, Recovered, Death) model and various scenarios for the first year after vaccination. The results showed that vaccination is cost-effective from a health care perspective, with an incremental cost-effectiveness ratio (ICER) of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced to only 50% of effectiveness on disease, respectively, at the 90% baseline effectiveness of the vaccine. From a societal perspective, cost savings were estimated for both scenarios. Other results further showed that the minimum required vaccine uptake to be cost-effective would be at least 30%. Sensitivity and scenario analyses, as well as the iso-ICER curves, showed that the results were quite robust and that major changes in cost-effectiveness outcomes cannot be expected. We can conclude that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving.

Sign in / Sign up

Export Citation Format

Share Document